Frank Igwealor

Torrance, CA (USA)
Role(s):
C-Level Executive (CEO, CFO, etc.)

CANNABINOID BIOSCIENCES, INC.

Find More Startups Startup
Location: Torrance
Industry: Healthcare
Year Founded: 2014
Number Employees: 10-50 people
Business Stage: Growth (not profitable)
Entity Type: "C" Corporation
Description: Cannabinoid Biosciences, Inc. (“KDCE”), a subsidiary of Kid Castle (OTC PINK: KDCE), California based Biopharmaceutical Company seeks to revolutionize and standardize the pharmaceuticals and non-pharmaceutical CBD products formulations and applications across the CBD market in the United States of America. Our business is divided into five segments namely: 1) CBD formulation, production, and distribution; 2) Biopharmaceutical Research and Development; 3) Investments into legal-cannabis businesses and deriving value from rollup/consolidation events that leads to IPO in US or Canada; 4) Financial products in form of asset-backed loans, business property mortgages and other financial products to qualified individuals/businesses in the legal-cannabis businesses. Current Financial Position We are currently raising $50 million to acquire 10 dispensaries, with $54 million in annual revenue, which we’ll rollup into our holding company and IPO on the NASDAQ or New York Stock Exchange; Our Regulation A+ T2 Offering Circular has been registered and was qualified by the US Securities and Exchange Commission (SEC) on April 16, 2019. KDCE has identified is seeking to buy 10 CBD operations, with $54 million in annual revenue, from their current owners for $49 million. A $1.00 invested with KDCE equity today could be worth approximately something between $21.5 to $215 after our value-adding rollup and consolidation activities with the acquisitions. We believe that a successful rollup as the one we are contemplating would fetch about $4.6 billion after consolidation and listing on NASDAQ or NYSE. Compared to investment in CURR, which trades at 327 times revenue or CURLF - Curaleaf Holdings, Inc., which is trading at 27 time revenue, your CBDZ investment would be at a big discount. If we apply CURLF multiples for CBDZ, the shares would be trading at $135 per share at IPO. If we apply CURR multiples for CBDZ, the shares would be trading at $1,635 per share at IPO. E.g., Cronos is currently trading at 209x sales. The investor would be getting for $1, a stock that has not be assigned the standard industry multiple of $131. That is ground floor of cannabis investment. Our process adds value based on current market trend. On August 15, 2018, Constellation Brands (STZ), invested $4 billion in Canopy Growth (CGC) for approximately 38% of Canopy. Canopy’s most recent annual reports showed the company has $73 million of revenue in its most recent fiscal year. STZ paid $144 times $1 of revenue of Canopy. On December 8, 2018, Altria, the manufacturer Marlboro cigarettes paid $1.8 billion for 45% stake of Cronos Group, Inc. (CRON), a Nasdaq-traded Canadian cannabis company with a number of dispensaries and cultivation facilities. Cronos’ most recent annual reports showed the company has $16 million of revenue in its most recent fiscal year. Thus, Altria paid $250 times $1 of revenue of Cronos. In pursuit our goal of getting listed or up-listed on the Nasdaq within the next 12 months, we acquired 70 million shares (voting control) of Kid Castle Educational Corporation (OTCPINK: KDCE) on October 21, 2019. See. (URL removed) See also. (URL removed) Since the disclosure of our acquisition, the stock price of KDCE has traded between $0.02 to $2.50, for a market cap of between $72 million and $250 million. Opportunity for capital appreciation: Acquisition of KDCE helped to validate our hypothesis about the potential capital appreciation. Our hypothesis on capital appreciation was validated on Friday, October 24, 2019. That morning, the SEC released our 8K filing disclosing that CBD concern has taking over KDCE. That news caused the stock price to spike as high as 8,000% before settling down and closing at 4,050% gain on the first day of its trade post-takeover by CBD operation. See. (URL removed) See also. (URL removed) The over 4,000% increase on the first day of trade was largely due to two factors namely: (1) Cannabiniod Biosciences, Inc., the acquirer is positioning itself to become the CBD king in the United States (being the first CBD Reg A+ to be qualified by the SEC).